Source: https://www.crowell.com/professionals/Keith-Harrison
Timestamp: 2019-04-24 16:47:40+00:00

Document:
Keith J. Harrison: False Claims Act/Whistleblower Lawyer: Washington, D.C.
Keith J. Harrison is a partner in the Health Care and Litigation practice groups in Crowell & Moring’s Washington, D.C. office. A former New York City prosecutor, Keith has tried numerous cases in eight states and the District of Columbia, and argued 14 cases as an appellate advocate. Keith maintains a diverse trial and arbitration practice, focused representing companies in highly-regulated industries, including health care, pharmaceutical, defense contracting, and aviation.
Keith currently devotes a considerable portion of his practice to identifying and developing affirmative recovery opportunities for health plans. Like the federal government, health plans are often the victims of health care fraud. Using his decades of experience in defending fraud and abuse, pharmaceutical pricing, and False Claims Act cases, Keith litigates, on a contingency basis, cases seeking to recover significant funds wrongfully obtained from health plans. Keith litigates False Claims Act (FCA), antitrust, anti-kickback, fraud and abuse,RICO, breach of contract, and other complex cases.He also represents clients in grand jury investigations and other proceedings before the DOJ. In addition, Keith has extensive experience representing clients in Congressional investigations and hearings.
This year, Keith was selected to receive the Washington Business Journal’s Minority Business Leader Award. The award recognizes the region’s top 25 minority business owners and leaders and for their “entrepreneurial drive, creativity, and success.” Keith has been repeatedly selected as a Washington, D.C. "Super Lawyer" in the field of civil litigation by Super Lawyers, from 2007 through 2018. Keith is also the co-chair of the firm's Public Service Practice Group and a member of the firm's Diversity Council. Prior to joining Crowell, Keith was a founding partner of King Pagano and Harrison, a 30 lawyer litigation boutique that merged with Crowell in 2006. For over a decade, Keith has been a faculty member of the National Institute for Trial Advocacy, and was one of the founders of Crowell's in-house Trial Excellence Academy, two institutions teaching lawyers the art of trial advocacy.
Represents as lead trial counsel a major health plan in an arbitration seeking to recover millions of dollars in prescription drugs reimbursement overpayments.
Represents a major generic pharmaceutical company in investigations of alleged price-fixing antitrust violations.
Represents United Airlines as lead trial and appellate counsel in United States ex rel. Grant v. United Airlines Inc., 912 F.3d 190, 198 (4th Cir. 2018), a qui tam whistleblower lawsuit alleging False Claims Act violations involving a $1.4 billion Air Force contract for the maintenance of C-17 aircraft engines where the Fourth Circuit dismissed the FCA allegations. This case is the current leading Fourth Circuit precedent regarding the pleading presentment of a false claim under the FCA.
Represents as lead trial counsel a drug manufacturer in United States ex rel.Cao v. West Ward Pharmaceuticals, 3:13-cv-03962 (D.N. J.)a qui tam whistleblower lawsuit alleging False Claims Act violations involving allegations of fraudulent pharmaceutical testing methods.
Lead national trial counsel for one of the world's largest generic drug manufacturers in the nationwide Average Wholesale Price litigation. During this time, Keith has coordinated the defense of more than 15 separate lawsuits pending in state and federal courts around the country, including a qui tam action under the Federal False Claims Act and numerous civil enforcement actions brought by state attorney general's alleging violations of a variety of state statutes, including state false claims acts.
Successfully represented a brand pharmaceutical company in a False Claims Act case alleging off-label marketing and FCA violations.
Successfully represented government defense contractor against allegations of fraudulent overcharging on aircraft armament firing systems.
Successfully represented, during a three-week jury trial, a government contractor accused of criminal false claims and money laundering related to the shipment of U.S. military equipment to Egypt under the Camp David Peace Accords and Foreign Military Sales program.
Successfully represented as lead trial counsel a major university in a whistleblower lawsuit that settled on the eve of trial.
Successfully represented a lead trial and appellate counsel a major hospital in a whistleblower case obtaining dismissal that was upheld on appeal in the leading case interpreting the District of Columbia’s public policy exception to at-will employment, Kassem v. Washington Hospital Center, 513 F.3d 251 (D.C. Cir. 2008).
Lead trial counsel for the plaintiff in Celera Genomics v. Wyeth, Inc., a breach of contract and fraud jury trial concerning Celera's historic decoding of the human genome and the licensing of its genetic database, which settled successfully after Keith's opening statement on behalf of Celera.
Developed a strategy for recovering Federal government underpayments to health plans participating in the Federal Employee Health Benefits Program (FEHBP). Eventually, over $350 million dollars in FEHBP underpayments were recovered for various health plans, including Kaiser Foundation Health Plans, United Health, HealthNet, NYLCare Health Plan and others.
Lead trial counsel in MorphoSys v. Cambridge Antibody Technology, where Keith successfully tried a three-week biotech patent infringement jury trial regarding phage display antibody library technology, the technology that eventually led to the blockbuster biologic drug HUMIRA®.
Represented as lead trial counsel a major U.S. airline in a multi-million dollar FAA regulatory dispute with the Port Authority of New York and New Jersey.
Represented airlines in disputes involving allegations of discrimination when airlines remove passengers identified as being security risks by the TSA.
Successfully resolved FAA enforcement proceedings against various airlines.
Obtained a TRO enjoining the sale of a commercial jet airliner in federal court.
Represented a major U.S. railroad company in antitrust litigation alleging price-fixing of fuel surcharges.
Represented AT&T in antitrust litigation bought by several phone companies alleging monopolization of essential facilities and refusal to deal in violation of Section 2 of the Sherman Act.
Won an arbitration victory against a world-renowned physician who claimed that a major hospital system was violating Section 1 of the Sherman Act in its relationships with physicians.
Successfully represented a pharmaceutical company in a Congressional investigation into the rising prices of certain generic drugs.
Represented Cotecna Inspection, S.A. and certain individual employees during the House, Senate and United Nations Volker Commission investigation into the U.N. Oil for Food Program and whether Cotecna's hiring of the U.N. Secretary General Kofi Annan's son, Kojo Annan, was an illegal kickback.
Represented a key witness testifying before the Cole Inquiry, a Royal Commission that investigated the Australian Wheat Board Oil-for-Wheat scandal (also known just as the AWB scandal) involving the payment of kickbacks to the regime of Saddam Hussein in contravention of the United Nations Oil-for-Food Humanitarian Program. The AWB was the biggest single source of kickbacks made to the Iraqi government and the scandal was the biggest bribery scheme in Australian history.
Represented the Executive Director of a trade association in an investigation by the House Energy and Commerce Subcommittee on Oversight and Investigations into waste, fraud and abuse in the Federal E-rate Program and DOJ investigation into violations of the antitrust laws.
Keith has decades of experience in conducting confidential investigations that have ranged from Major League Baseball's investigation of Pete Rose to the United Nations Iraq Oil for Food Program.
Currently conducting internal investigations of potential FCA violations for companies in the pharmaceutical, and aviation industries.
Conducted internal investigations regarding missing funds from a major armored car company.
Conducted internal investigations regarding allegations of sexual harassment against a corporate CEO.
Conducted an internal investigation of a Department Chairman of a major hospital system for fraud related to medical accreditation activities.
Recently represented the world's largest water treatment company in obtaining a temporary restraining order (TRO) and then a permanent injunction against the EPA and DOJ that prevented the federal government from enforcing a stop-sale order and allowed a multi-million dollar water treatment technology back on the market.
Lead trial counsel in NAACP v. Alabama, 2:16-cv-00731 (M.D. AL), seeking to apply Section 2 of the Voting Rights Act of 1964 to the dilution of African-American votes in state-wide elections for the Alabama Supreme Court, Court of Civil Appeals and Court of Criminal Appeals.
Lead trial counsel in Crosley Green v. Secretary, Department of Corrections seeking to the obtain the release and overturn the conviction of an innocent man who was on Florida's Death Row for 20 years, and has been wrongfully imprisoned for 28 years. This case was featured on a CBS 48 Hours episode entitled, “Crosley Green’s Last Chance for Freedom,”.
Obtained U.S. asylum for a Christian Pastor and his family from the Democratic Republic of the Congo, who was repeatedly tortured in response to his preaching for social justice and respect for democratic constitutional values.
The City Council for the District of Columbia retained Keith to investigate allegations that the D.C. Police Department was failing to investigate and mishandling sexual assault cases. The firm's investigation led to police reforms and new legislation entitled, "Sexual Assault Victims' Rights Act of 2013."
"The Rearview Mirror: Lessons Learned From This Year's Trial Victories," Crowell & Moring Seminar/Webinar (April 22, 2014). Presenters: Robert T. Rhoad, Gregory D. Call, Kevin C. Mayer, Linda B. Popejoy, Keith J. Harrison, Brian Tully McLaughlin, Mana Elihu Lombardo, Nathaniel P. Bualat, and Jeffrey H. Rutherford.
"Navigating High-Profile Litigation and Administrative Enforcement," Crowell & Moring Advertising and Product Risk Management Seminar (March 19, 2013). Moderator: Andrew Kaplan; Panelists: Kevin C. Mayer, Keith J. Harrison, and John Fuson.
"Piling On: Whistleblower Statutes Run Amok," Minority Corporate Counsel Association's 11th Annual CLE Expo, Chicago (March 21, 2012). Presenter: Keith J. Harrison.
"U.S. Healthcare Reform: What's in it for Biosimilars?" European Generics Medicines Association's 8th Annual Symposium on Biosimilars, London (September 8-10, 2010). Presenter: Keith J. Harrison.
"Mapping Out The Latest Developments in European And US Biosimilar Regulation-Achieving Cost Effective Compliance," Biosimilars India 2009 Conference (December 2, 2009). Presenter: Keith J. Harrison.
"California State Whistleblower Claim Nets $30 Million Anti-Kickback Settlement from Life Sciences Company," Crowell & Moring's Whistleblower Watch (July 25, 2016). Authors: Keith Harrison and Jason M. Crawford.
"Don't Hold Back: The FTC Attacks Endo for Agreeing to Delay Launch of an Authorized Generic," Bloomberg BNA's Pharmaceutical Law & Industry Report (May 13, 2016). Authors: Keith J. Harrison, James K. Stronski, Olivier N. Antoine, Astor Heaven, and Anne Elise Herold Li.
"Jurisdictional Analysis - Time to Trial, Favorable Courts & Other Litigation Trends," Crowell & Moring's Litigation Forecast 2016 (January 2016). Author: Keith Harrison.
"A Comparative Analysis of the United States Biosimilar Pathway," American Health Lawyers Association (July 2010). Author: Keith J. Harrison.
"International Arbitration In The Middle East: A Case Study of Qatar," The International Dispute Resolution News, Vol. 1, No. 1 (Fall 2009). Authors: Meriam N. Alrashid, Keith J. Harrison, Brian E. Abrams, and Jonas B. Lerman.
Case of Crosley Green: Was An Innocent Man Convicted of Murder 25 Years Ago?

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.